High cholesterol medication names
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
High Cholesterol Medication Names: An Overview
Statins: The Primary Cholesterol-Lowering Drugs
Statins are the most commonly prescribed medications for lowering cholesterol levels. They work by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Common statins include:
- Simvastatin: The most frequently used statin, reported by 42% of cholesterol-lowering medication users.
- Atorvastatin: The second most common, used by 20.2% of users.
- Rosuvastatin: Another widely used statin, often prescribed for its potent cholesterol-lowering effects.
Generic vs. Brand-Name Statins
A study comparing generic and brand-name statins found that patients on brand-name statins had better treatment persistence and adherence. This led to more patients reaching their LDL-c goals and a lower incidence of major cardiovascular events and all-cause mortality. The study highlighted the economic and health benefits of brand-name statins over generics in routine medical practice in Spain.
Fibrates and Niacin: HDL-C Increasing Drugs
Fibrates and niacin are other classes of drugs used to manage cholesterol levels, particularly for increasing high-density lipoprotein cholesterol (HDL-C):
- Fibrates: These drugs, such as gemfibrozil, are effective in reducing triglycerides and increasing HDL-C levels. They have been shown to reduce the risk of major coronary events by 25% .
- Niacin: Known for its potent effect on raising HDL-C levels, niacin also reduces triglycerides and LDL-C. However, its impact on reducing cardiovascular events is less clear, especially when used alongside statins .
CETP Inhibitors: Emerging Therapies
Cholesteryl ester transfer protein (CETP) inhibitors are a newer class of drugs designed to increase HDL-C levels. Examples include:
- Torcetrapib: This CETP inhibitor significantly raises HDL-C levels but has shown mixed results in clinical outcomes .
- Evacetrapib: Another CETP inhibitor that increases HDL-C and improves cholesterol efflux capacity, though its long-term benefits on cardiovascular outcomes require further study.
Combination Therapies
Combining different cholesterol-lowering medications can enhance their efficacy. For instance, combining ETC-1002 with ezetimibe has been shown to significantly reduce LDL-C levels more than ezetimibe alone, offering a promising option for patients with or without statin intolerance.
Conclusion
Statins remain the cornerstone of cholesterol-lowering therapy, with simvastatin and atorvastatin being the most commonly used. While generic statins are more cost-effective, brand-name statins may offer better adherence and outcomes. Fibrates and niacin are valuable for increasing HDL-C, and emerging CETP inhibitors like torcetrapib and evacetrapib show potential, though their long-term benefits need further validation. Combination therapies also present a viable strategy for managing high cholesterol, particularly in patients with statin intolerance.
Sources and full results
Most relevant research papers on this topic